跳到主要內容

臺灣博碩士論文加值系統

(44.222.218.145) 您好!臺灣時間:2024/03/04 16:40
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:劉晉育
研究生(外文):Chin-Yu Liu
論文名稱:2-(3-Hydroxyphenyl)-5-methyl-1,8-naphathyridin-4(1H)-one及其相關化合物的合成與抗癌活性
論文名稱(外文):Synthesis and Anticancer Activity of 2-(3-Hydroxyphenyl)-5-methyl-1,8-naphathyridin-4(1H)-one and its Related Compounds
指導教授:郭盛助郭盛助引用關係
指導教授(外文):Sheng-Chu Kuo
學位類別:博士
校院名稱:中國醫藥大學
系所名稱:藥物化學研究所博士班
學門:醫藥衛生學門
學類:藥學學類
論文種類:學術論文
論文出版年:2013
畢業學年度:101
語文別:中文
論文頁數:220
中文關鍵詞:抗腫瘤羥基衍生物磷酸前驅藥
外文關鍵詞:Hydroxy substituted 2-aryl-18-naphathyridin-4-onephosphate prodrugHep3B cancer cell line
相關次數:
  • 被引用被引用:0
  • 點閱點閱:146
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
第一部分:為了從2-aryl-1,8-naphthyridin-4-ones(2-AN)系列化合物探索新抗癌候選藥物,著者設計並合成了一系列3′-hydroxy或6-hydroxy取代的2-AN衍生物,其中大部分的化合物對腫瘤細胞株都展現了顯著的細胞毒性,尤其是2-(3-hydroxyphenyl)-5-methyl-1,8-naphathyridine- 4(1H)-one(7a)最具發展潛力,初步的藥理作用機轉結果顯示7a影響Hep3B細胞株之微管及轉移相關蛋白,另外化合物7a的磷酸化前驅藥11,對Hep3B xenograft animal model展現顯著的抗腫瘤活性,因此化合物11深具潛力足以繼續進行臨床前研究。
第二部分:本研究的主要目的在探討KHL-1抑制肝細胞癌細胞株Hep3B細胞生長之作用機制。利用cDNA微陣列與西方點墨法去偵測KHL-1所造成的基因與蛋白表現變化。結果顯示,KHL-1會造成Hep3B細胞生長抑制、細胞形態改變、細胞週期G2/M期停滯,以及細胞凋亡作用。cDNA 微陣列分析結果顯示,許多與細胞生長、血管新生、細胞自噬作用、鈣離子引起的內質網壓力相關訊息路徑、細胞黏附作用、細胞週期、減數分裂、細胞移行作用、細胞骨架排列、DNA損壞與修復、粒腺體凋亡,以及細胞訊號路徑相關的基因表現量會受到KHL-1的影響。此外,KHL-1會降低CDK1活性、增加細胞內鈣離子濃度、caspase-4、caspase-9 與caspase-3的活性。西方點墨法結果顯示,KHL-1會增加caspase-4與GADD153的蛋白表現量,這可能會促使內質網壓力增加,進而促進Hep3B細胞的凋亡作用。因此,KHL-1經由促使G2/M期停滯、鈣離子增加引起的內質網壓力,以及活化粒腺體凋亡路徑等機制,以抑制Hep3B細胞的生長。

Part1:To develop new antitumor drug candidates from 2-aryl-1,8- naphthyridin-4-ones (2-AN), we have designed and synthesized 3''-hydroxy or 6-hydroxy 2-AN derivatives. Most of the new compounds exhibited significant cytotoxicity against cancer cell lines. Among them, 2-(3-hydroxyphenyl)-5-methyl-1,8-naphthyridin-4(1H)-one (7a) was the most promising. In the preliminary mechanism of action study, treatment of Hep3B hepatoma cells with 7a showed effects on microtubules and metastasis-related proteins. In addition, the phosphate prodrug 11 of 7a exhibited significant antitumor activity when tested in a Hep3B xenograft nude mice model. Therefore, compound 11 has good development potential and is recommended for further preclinical studies.
Part2:In the present study, we investigated the antitumor effects of KHL-1 on the viability, cell cycle and apoptotic cell death in human epatocellular carcinoma Hep3B cells in vitro. We also investigated the molecular mechanisms involved in the effects of KHL-1 on human hepatoma Hep3B cells, including the effects on protein and mRNA levels which were determined by western blotting and DNA microarray methods, respectively. The results demonstrated that KHL-1 induced growth inhibition, cell morphological changes and induction of G2/M arrest and apoptosis in Hep3B cells. DNA microarray assay identified numerous differentially expressed genes related to angiogenesis, autophagy, calcium-mediated ER stress signaling, cell adhesion, cell cycle and mitosis, cell migration, cytoskeleton organization, DNA damage and repair, mitochondrial-mediated apoptosis and cell signaling pathways. Furthermore, KHL-1 inhibited CDK1 activity, mitochondrial membrane potential (ΔΨm) and increased the cytosolic Ca2+ release and caspase-4, caspase-9 and caspase-3 activities in Hep3B cells. Western blot analysis demonstrated that KHL-1 increased the protein levels of caspase-4 and GADD153 that may lead to ER stress and consequently apoptosis in Hep3B cells. Taken together, KHL-1 acts against human hepatocellular carcinoma Hep3B cells in vitro through G2/M phase arrest and induction of calcium-mediated ER stress and mitochondrial-dependent apoptotic signaling pathways.

第一部分目錄
目錄.....i
圖目錄.....iii
表目錄.....viii
縮寫表.....ix
中文摘要.....x
英文摘要.....xi
第一章 緒論.....1
第一節 2-Aryl-1,8-naphthyridin-4(1H)-one類化合物.....1
第二節 Phosphate prodrug之特性.....13
第二章 研究動機與目的.....17
第三章 結果與討論.....19
第一節 標的化合物之合成.....19
第二節 藥理活性測試結果.....39
第四章 結論.....68
第五章 實驗部分.....69
第一節 試藥與溶媒.....69
第二節 重要儀器與實驗材料.....74
第三節 各化合物之製備.....77
第四節 藥理實驗方法.....123
參考文獻.....127
化合物光譜資料.....133
第二部分目錄
目錄.....xii
圖目錄.....xiv
表目錄.....xvi
縮寫表.....xvii
中文摘要.....xviii
英文摘要.....xix
第一章 緒論.....159
第一節 細胞週期.....159
第二節 細胞凋亡.....162
第三節 內質網壓力.....164
第二章 研究動機與目的.....166
第三章 結果與討論.....167
第一節 KHL-1的製備.....167
第二節 藥理活性實驗結果.....169
第四章 結論.....189
第五章 實驗部分.....190
第一節 試藥與溶媒.....190
第二節 重要儀器與實驗材料.....194
第三節 目標化合物之製備.....196
第四節 化合物之光譜資料.....199
第五節 藥理實驗方法.....202
參考文獻.....206
化合物光譜資料.....216


第一部分參考文獻
1.Chen, K.; Kuo, S. C.; Hsieh, M. C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H., Antitumor Agents. 174. 2’,3’,4’,5,6,7-Substituted 2-Phenyl-1,8-naphthyridin-4-ones: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization1. J. Med. Chem. 1997, 40 (14), 2266-2275.
2.Chen, K.; Kuo, S. C.; Hsieh, M. C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H., Antitumor Agents. 178. Synthesis and Biological Evaluation of Substituted 2-Aryl-1,8-naphthyridin-4(1H)-ones as Antitumor Agents That Inhibit Tubulin Polymerization. J. Med. Chem. 1997, 40 (19), 3049-3056.
3.Zhang, S. X.; Bastow, K. F.; Tchibana, Y.; Kuo, S. C.; Hamel, E.; Mauger, A.; Narayanan, V. L.; Lee, K. H., Antitumor Agents. 196. Substituted 2-Thienyl-1,8-naphthyridin-4-ones: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization. J. Med. Chem. 1999, 42 (20), 4081-4087.
4.Ferrarini, P. L.; Mori, C.; Manera, C.; Martinelli, A.; Mori, F.; Saccomanni, G.; Barili, P. L.; Betti, L.; Giannaccini, G.; Trincavelli, L.; Lucacchini, A., A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives. J. Med. Chem. 2000, 43 (15), 2814-2823.
5.Ferrarini, P. L.; Betti, L.; Cavallini, T.; Giannaccini, G.; Lucacchini, A.; Manera, C.; Martinelli, A.; Ortore, G.; Saccomanni, G.; Tuccinardi, T., Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J. Med. Chem. 2004, 47 (12), 3019-3031.
6.Zografos, A. L.; Mitsos, C. A.; Igglessi-Markopoulou, O., Chemoselective cyclization of aminonicotinic acid derivatives to 1,8-naphthyridin-2-ones via a potential intramolecular azadiene-ketene electrocyclization reaction. J. Org. Chem. 2001, 66 (12), 4413-4415.
7.Pidathala, C.; Amewu, R.; Pacorel, B.; Nixon, G. L.; Gibbons, P.; Hong, W. D.; Leung, S. C.; Berry, N. G.; Sharma, R.; Stocks, P. A.; Srivastava, A.; Shone, A. E.; Charoensutthivarakul, S.; Taylor, L.; Berger, O.; Mbekeani, A.; Hill, A.; Fisher, N. E.; Warman, A. J.; Biagini, G. A.; Ward, S. A.; O''Neill, P. M., Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2). J. Med. Chem. 2012, 55 (5), 1831-1843.
8.Iaroshenko, V. O.; Knepper, I.; Zahid, M.; Kuzora, R.; Dudkin, S.; Villinger, A.; Langer, P., Efficient [5 + 1]-strategy for the assembly of 1,8-naphthyridin-4(1H)-ones by domino amination/conjugate addition reactions of 1-(2-chloropyridin-3-yl)prop-2-yn-1-ones with amines. Org. Biomol. Chem. 2012, 10 (15), 2955-2959.
9.Iaroshenko,V. O.; Zahid, M.; Mkrtchyan, S.; Gevorgyan, A.; Altenburger, K.; Knepper, I.; Villinger, A.; Sosnovskikh, V. Y.; Langer, P., Efficient synthesis of novel benzo[b][1,8]naphthyridin-4(1H)-ones and pyrido[2,3-b]quinoxalin-4(1H)-ones from alkynones and primary amines Tetrahedron, 2013, 69, 2309-2318
10.Abdullah, N. M.; Rosania, G. R.; Shedden, K., Selective targeting of tumorigenic cancer cell lines by microtubule inhibitors. Plos One 2009, 4 (2), 4470-4477.
11.Chou, L. C.; Chen, C. T.; Lee, J. C.; Way, T. D.; Huang, C. H.; Huang, S. M.; Teng, C. M.; Yamori, T.; Wu, T. S.; Sun, C. M.; Chien, D. S.; Qian, K.; Morris-Natschke, S. L.; Lee, K. H.; Huang, L. J.; Kuo, S. C., Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7- methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. J. Med. Chem. 2010, 53 (4), 1616-1626.
12.Chen, K.; Wang, K.; Kirichian, A. M.; Al Aowad, A. F.; Iyer, L. K.; Adelstein, S. J.; Kassis, A. I., In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase-mediated cancer diagnosis and therapy. Mol. Cancer Ther. 2006, 5 (12), 3001-3013.
13.Yuan, H.; Li, N.; Lai, Y., Evaluation of in vitro models for screening alkaline phosphatase-mediated bioco nversion of phosphate ester prodrugs. Drug metabolism and disposition 2009, 37 (7), 1443-1447.
14.Saulnier, M. G.; L angley, D. R.; Kadow, J. F.; Senter, P. D.; Knipe, J. O.; Tun, M. M.; Vyas, D. M.; Doyle, T. W., Synthesis of etoposide phosphate, BMY-40481: A water-soluble clinically active prodrug of etoposide. Bioorg. Med. Chem. Lett. 1994, 4, 2567-2572
15.Grosios, K.; Holwell, S. E.; McGown, A. T.; Pettit, G. R.; Bibby, M. C., In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 1999, 81 (8), 1318-1327.
16.de Jong, R. S.; Slijfer, E. A.; Uges, D. R.; Mulder, N. H.; de Vries, E. G., Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile. Br. J. Cancer 1997, 76 (11), 1480-1483.
17.Mészáros, Z.; Hermecs, I. Nitrogen bridgehead compounds Ⅲ. New ring transformation Ⅰ. Tetrahedron Lett. 1975, 12, 1019-1020.
18.Mészáros, Z.; Hermecs, I.; Simon, K. Nitrogen bridgehead compounds. Part 41. ring transformation of Nitrogen bridgehead ring systems. J. Chem. Soc. Perkin Trans. 1. 1984, 1795-1798.
19.Debrecy, L. V.; Hermecs, I.; Mészáros, Z.; Dvortsák, P. Nitrogen bridgehead compounds. Part 6. ring transformation. Part 3. Thermal cyclization of diethyl 2-(2-pyridylaminomethylene)-succinates and glutarates. J. Chem. Soc. Perkin Trans. 1. 1980, 227-232.
20.Ferrarini, P. L.; Mori, C.; Livi, O.; Biagi, G.; Marini, A. M. Synthesis of some substitued pyrido[1,2-a]pyrimidin-4-one and 1,8- naphthyridines. J. Heterocycl. Chem. 1983, 20, 1053-1057.
21.Hermecs, I.; Horváth, Á. Nitrogen bridgehead compounds. Part 83. systhesis and ring transformation of 6-methyl-4-oxo-4H-pyrido[1,2-a] pyrimidine-3-acrylate. J. Heterocycl. Chem. 1992, 29, 559-564.
22.Kuo, S. C.; Lee, H. Z.; Juang, J. P.; Lin, Y. T.; Wu, T. S.; Chang, J. J.; Lednicer, D.; Paull, K. D.; Lin, C. M.; Hamel, E.; Lee, K.-H., Synthesis and Cytotoxicity of 1,6,7,8-Substituted 2-(4''-Substituted phenyl)-4-quinolones and Related Compounds: Identification as Antimitotic Agents Interacting with Tubulin. J. Med. Chem. 1993, 36 (9), 1146-1156.
23.Cheng, Y. Y.; Liu, C. Y.; Huang, L. J.; Huang, C. H.; Lee, K. H.; Lin, C. L.; Kuo, S. C., Mechanistic studies on regioselective dephosphorylation of phosphate prodrugs during a facile synthesis of antitumor phosphorylated 2-phenyl-6,7-methylenedioxy-1H-quinolin- 4-one. Molecules 2013, 18 (7), 8028-8045.
24.Bhattacharyya B.; Panda D.; Gupta S.; Banerjee M., Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med. Res. Rev. 2008, 28, 155-183.
25.Jordan M. A.;Wilson L., Microtubules as a target for antitumor drugs. Nat. Rev. Cancer. 2004, 4, 253-265.
26.Downing K. H.;Nogales E., Tubulin structure: insights into microtubule properties and functions. Curr. Opin. Struct. Bio. 1998, 8, 785-791.
27.Sorger P. K.;Dobles M.;Tournebize R.; Hyman A. A., Coupling cell division and cell death to microtubule dynamics. Curr.Opin. Cell Biol. 1997, 9, 807-814.
28.Meunier S.; and Vernos I., Microtubule assembly during mitosis-from distinct origins to distinct functions. J. Cell Sci. 2012, 125, 2805-2814.
29.Pasquier E.;Kavallaris M., Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008, 60, 165-170.
30.Morris P. G.;Fornier M. N., Microtubule active agents: beyond the taxane frontier. Clin. Cancer Res. 2008, 14, 7167-7172.
第二部分參考文獻
1.Moriguchi, M.; Takayama, T.; Higaki, T.; Kimura, Y.; Yamazaki, S.; Nakayama, H.; Ohkubo, T.; Aramaki, O., Early cancer-related death after resection of hepatocellular carcinoma. Surgery 2012, 151 (2), 232-237.
2.Chen, T. H.; Chen, C. J.; Yen, M. F.; Lu, S. N.; Sun, C. A.; Huang, G. T.; Yang, P. M.; Lee, H. S.; Duffy, S. W., Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int. J. Cancer 2002, 98 (2), 257-261.
3.Ueda, H.; Fukuchi, H.; Tanaka, C., Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). Oncol. Lett. 2012, 3 (2), 259-263.
4.Blum, H. E., Hepatocellular carcinoma: HCC. Hepat Mon 2011, 11 (2), 69-70.
5.Abou-Alfa, G. K., New agents in hepatocellular carcinoma. Clin. Adv. Hematol. Oncol. 2008, 6 (6), 423-424.
6.Marquardt, J. U.; Galle, P. R.; Teufel, A., [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy]. Dtsch. Med. Wochenschr. 2012, 137 (16), 855-860.
7.Hoshida, Y.; Toffanin, S.; Lachenmayer, A.; Villanueva, A.; Minguez, B.; Llovet, J. M., Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010, 30 (1), 35-51.
8.Shah, M. A.; Schwartz, G. K., Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2001, 7 (8), 2168-2181.
9.Dehay, C.; Kennedy, H., Cell-cycle control and cortical development. Nat. Rev. Neuroscience 2007, 8 (6), 438-450.
10.Okada, H.; Mak, T. W., Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4 (8), 592-603.
11.Brown, J. M.; Attardi, L. D., The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 2005, 5 (3), 231-237.
12.Fesik, S. W., Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5 (11), 876-885.
13.Degterev, A.; Yuan, J., Expansion and evolution of cell death programmes. Nat. Rev. Mol. Cell. Biol. 2008, 9 (5), 378-390.
14.Fulda, S.; Debatin, K. M., Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25 (34), 4798-4811.
15.Li, Q. X.; Yu, D. H.; Liu, G.; Ke, N.; McKelvy, J.; Wong-Staal, F., Selective anticancer strategies via intervention of the death pathways relevant to cell transformation. Cell Death Differ. 2008, 15 (8), 1197-1210.
16.Hogstrand, K.; Hejll, E.; Sander, B.; Rozell, B.; Larsson, L.G.; Grandien, A., Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumori-genesis towards acute myeloid leukemia. 2012, PLoS One 7, e31366
17.Poellinger, L.; Lendahl, U., Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Curr. Opin. Genet. Dev. 2008, 18 (5), 449-454.
18.Harding, H. P.; Ron, D., Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002, 51 Suppl 3, S455-461.
19.Kim, M. K.; Kim, H. S.; Lee, I. K.; Park, K. G., Endoplasmic reticulum stress and insulin biosynthesis: a review. Exp. Diabetes Res. 2012, 2012, 509437.
20.Gregor, M. F.; Hotamisligil, G. S., Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J. Lipid. Res. 2007, 48 (9), 1905-1914.
21.Oyadomari, S.; Mori, M., Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11 (4), 381-389.
22.Nozaki, S.; Sledge Jr, G. W.; Nakshatri, H., Repression of GADD153/CHOP by NF-kappaB: a possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene 2001, 20 (17), 2178-2185.
23.Chakrabarti, A.; Chen, A. W.; Varner, J. D., A review of the mammalian unfolded protein response. Biotechnol. Bioeng. 2011, 108 (12), 2777-2793.
24.Shore, G. C.; Papa, F. R.; Oakes, S. A., Signaling cell death from the endoplasmic reticulum stress response. Curr. Opin. Cell Biol. 2011, 23 (2), 143-149.
25.Endo, H.; Murata, K.; Mukai, M.; Ishikawa, O.; Inoue, M., Activation of insulin-like growth factor signaling induces apoptotic cell death under prolonged hypoxia by enhancing endoplasmic reticulum stress response. Cancer Res. 2007, 67 (17), 8095-8103.
26.Obeng, E. A.; Boise, L. H., Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmic reticulum stress-induced apoptosis. J. Biol. Chem. 2005, 280 (33), 29578-29587.
27.Wang, L.; Wang, L.; Song, R.; Shen, Y.; Sun, Y.; Gu, Y.; Shu, Y.; Xu, Q., Targeting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol. Cancer. Ther. 2011, 10 (3), 461-471.
28.Wu, Z.; Liang, F.; Hong, B.; Young, J. C.; Sussman, M. R.; Harper, J. F.; Sze, H., An endoplasmic reticulum-bound Ca(2+)/Mn(2+) pump, ECA1, supports plant growth and confers tolerance to Mn(2+) stress. Plant Physiol. 2002, 130 (1), 128-137.
29.Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J., Prodrugs: design and clinical applications. Nat. Rev. Drug discovery 2008, 7 (3), 255-270.
30.Ni, C. H.; Chen, P. Y.; Lu, H. F.; Yang, J. S.; Huang, H. Y.; Wu, S. H.; Ip, S. W.; Wu, C. T.; Chiang, S. Y.; Lin, J. G.; Wood, W. G.; Chung, J. G., Chrysophanol-induced necrotic-like cell death through an impaired mitochondrial ATP synthesis in Hep3B human liver cancer cells. Arch. Pharm. Res. 2012, 35 (5), 887-895.
31.Tsai, S. C.; Yang, J. S.; Peng, S. F.; Lu, C. C.; Chiang, J. H.; Chung, J. G.; Lin, M. W.; Lin, J. K.; Amagaya, S.; Wai-Shan Chung, C.; Tung, T. T.; Huang, W. W.; Tseng, M. T., Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. Int. J. Oncol. 2012, 41 (4), 1431-1442.
32.Huang, S. M.; Cheng, Y. Y.; Chen, M. H.; Huang, C. H.; Huang, L. J.; Hsu, M. H.; Kuo, S. C.; Lee, K. H., Design and synthesis of 2-(3-alkylaminophenyl)-6-(pyrrolidin-1-yl)quinolin-4-ones as potent antitumor agents. Bioorg. Med. Chem. Lett. 2013, 23 (3), 699-701.
33.Shih-Ming Huang, J.-S. Y., Shih-Chang Tsai, Ming-Hua Chen, Mei-Hua Hsu, Hui-Yi Lin, Li-Chen Chou, Jo-Hua Chinag, Kuo-Hsiung Lee, Li-Jiau Huang, Sheng-Chu Kuo, The novel synthesized 2-(3-(methylamino)phenyl)-6-(pyrrolidin-1-yl)quinolin-4- one (Smh-3) compound induces G2/M phase arrest and mitochondrial-dependent apoptotic cell death through inhibition of CDK1 and AKT activity in HL-60 human leukemia cells. Int. J. Oncol . 2011, 38 (5), 1357-1364.
34.Lin, J. P.; Yang, J. S.; Chang, N. W.; Chiu, T. H.; Su, C. C.; Lu, K. W.; Ho, Y. T.; Yeh, C. C.; Mei, D.; Lin, H. J.; Chung, J. G., GADD153 mediates berberine-induced apoptosis in human cervical cancer Ca ski cells. Anticancer Res. 2007, 27 (5A), 3379-3386.
35.Lu, H. F.; Hsueh, S. C.; Ho, Y. T.; Kao, M. C.; Yang, J. S.; Chiu, T. H.; Huamg, S. Y.; Lin, C. C.; Chung, J. G., ROS mediates baicalin-induced apoptosis in human promyelocytic leukemia HL-60 cells through the expression of the Gadd153 and mitochondrial-dependent pathway. Anticancer Res. 2007, 27 (1A), 117-125.
36.Chambers, K. T.; Unverferth, J. A.; Weber, S. M.; Wek, R. C.; Urano, F.; Corbett, J. A., The role of nitric oxide and the unfolded protein response in cytokine-induced beta-cell death. Diabetes 2008, 57 (1), 124-132.
37.Kim, R.; Emi, M.; Tanabe, K.; Murakami, S., Role of the unfolded protein response in cell death. Apoptosis 2006, 11 (1), 5-13.
38.Huang, W. W.; Chiu, Y. J.; Fan, M. J.; Lu, H. F.; Yeh, H. F.; Li, K. H.; Chen, P. Y.; Chung, J. G.; Yang, J. S., Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma U-2 OS cells. Mol. Nut.r Food Res. 2010, 54 (11), 1585-1595.
39.Lu, C. C.; Yang, J. S.; Chiang, J. H.; Hour, M. J.; Lin, K. L.; Lin, J. J.; Huang, W. W.; Tsuzuki, M.; Lee, T. H.; Chung, J. G., Novel quinazolinone MJ-29 triggers endoplasmic reticulum stress and intrinsic apoptosis in murine leukemia WEHI-3 cells and inhibits leukemic mice. Plos One 2012, 7 (5), e36831.
40.Schattenberg, J. M.; Schuchmann, M.; Galle, P. R., Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. J. Gastroenterol. Hepatol . 2011, 26 Suppl 1, 213-219.
41.Rosello, A.; Warnes, G.; Meier, U. C., Cell death pathways and autophagy in the central nervous system and its involvement in neurodegeneration, immunity and central nervous system infection: to die or not to die--that is the question. Clin. Exp. Immunol. 2012, 168 (1), 52-57.
42.Huang, W. W.; Yang, J. S.; Lin, M. W.; Chen, P. Y.; Chiou, S. M.; Chueh, F. S.; Lan, Y. H.; Pai, S. J.; Tsuzuki, M.; Ho, W. J.; Chung, J. G., Cucurbitacin E Induces G(2)/M Phase Arrest through STAT3/p53/p21 Signaling and Provokes Apoptosis via Fas/CD95 and Mitochondria-Dependent Pathways in Human Bladder Cancer T24 Cells. Evid Based Complement Alternat Med 2012, 2012, 952762.
43.Hour, M. J.; Tsai, S. C.; Wu, H. C.; Lin, M. W.; Chung, J. G.; Wu, J. B.; Chiang, J. H.; Tsuzuki, M.; Yang, J. S., Antitumor effects of the novel quinazolinone MJ-33: Inhibition of metastasis through the MAPK, AKT, NF-kappaB and AP-1 signaling pathways in DU145 human prostate cancer cells. Int. J. Oncol. 2012, 41 (4), 1513-1519.
44.Yaguchi, T.; Saito, M.; Yasuda, Y.; Nishizaki, T., Caspase-4 activation in association with decreased adenosine deaminase activity may be a factor for gastric ulcer. Digestion 2010, 81 (1), 62-67.
45.Wu, S. H.; Hang, L. W.; Yang, J. S.; Chen, H. Y.; Lin, H. Y.; Chiang, J. H.; Lu, C. C.; Yang, J. L.; Lai, T. Y.; Ko, Y. C.; Chung, J. G., Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res. 2010, 30 (6), 2125-2133.



QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top